These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 12808880

  • 1. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes.
    Wiedeman PE, Trevillyan JM.
    Curr Opin Investig Drugs; 2003 Apr; 4(4):412-20. PubMed ID: 12808880
    [Abstract] [Full Text] [Related]

  • 2. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
    Pei Z.
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
    [Abstract] [Full Text] [Related]

  • 3. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
    Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Tanaka I.
    Metabolism; 2003 Jan; 52(1):81-6. PubMed ID: 12524666
    [Abstract] [Full Text] [Related]

  • 4. Newly approved and promising antidiabetic agents.
    Combettes M, Kargar C.
    Therapie; 2007 Jan; 62(4):293-310. PubMed ID: 17983555
    [Abstract] [Full Text] [Related]

  • 5. Incretins and other peptides in the treatment of diabetes.
    Todd JF, Bloom SR.
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [Abstract] [Full Text] [Related]

  • 6. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
    Diamant M, Bunck MC, Heine RJ.
    Ned Tijdschr Geneeskd; 2004 Sep 25; 148(39):1912-7. PubMed ID: 15495988
    [Abstract] [Full Text] [Related]

  • 7. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
    Triplitt C, Wright A, Chiquette E.
    Pharmacotherapy; 2006 Mar 25; 26(3):360-74. PubMed ID: 16503716
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats.
    Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T, Tanaka I.
    J Pharmacol Exp Ther; 2004 Aug 25; 310(2):614-9. PubMed ID: 15039452
    [Abstract] [Full Text] [Related]

  • 10. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?
    McIntosh CH, Demuth HU, Pospisilik JA, Pederson R.
    Regul Pept; 2005 Jun 15; 128(2):159-65. PubMed ID: 15780435
    [Abstract] [Full Text] [Related]

  • 11. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.
    Deacon CF, Holst JJ.
    Int J Biochem Cell Biol; 2006 Jun 15; 38(5-6):831-44. PubMed ID: 16242377
    [Abstract] [Full Text] [Related]

  • 12. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
    Langley AK, Suffoletta TJ, Jennings HR.
    Pharmacotherapy; 2007 Aug 15; 27(8):1163-80. PubMed ID: 17655515
    [Abstract] [Full Text] [Related]

  • 13. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
    Kirby M, Yu DM, O'Connor S, Gorrell MD.
    Clin Sci (Lond); 2009 Sep 28; 118(1):31-41. PubMed ID: 19780719
    [Abstract] [Full Text] [Related]

  • 14. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus.
    McIntosh CH, Demuth HU, Kim SJ, Pospisilik JA, Pederson RA.
    Int J Biochem Cell Biol; 2006 Sep 28; 38(5-6):860-72. PubMed ID: 16442340
    [Abstract] [Full Text] [Related]

  • 15. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.
    Idris I, Donnelly R.
    Diabetes Obes Metab; 2007 Mar 28; 9(2):153-65. PubMed ID: 17300591
    [Abstract] [Full Text] [Related]

  • 16. Glucagon-like peptide-1 derivatives and dipeptidyl peptidase-IV inhibitors. New hope for the treatment of type-2 diabetes.
    Al-Omar MA, Al-Arifi MN.
    Saudi Med J; 2005 Oct 28; 26(10):1511-5. PubMed ID: 16228047
    [Abstract] [Full Text] [Related]

  • 17. Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement.
    Mest HJ.
    Curr Opin Investig Drugs; 2006 Apr 28; 7(4):338-43. PubMed ID: 16625820
    [Abstract] [Full Text] [Related]

  • 18. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD, Gault VA, O'Harte FP, Flatt PR.
    Diabetes Obes Metab; 2005 Sep 28; 7(5):595-604. PubMed ID: 16050953
    [Abstract] [Full Text] [Related]

  • 19. The role of vildagliptin in the management of type 2 diabetes mellitus.
    Kleppinger EL, Helms K.
    Ann Pharmacother; 2007 May 28; 41(5):824-32. PubMed ID: 17456545
    [Abstract] [Full Text] [Related]

  • 20. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes.
    Nielsen LL.
    Drug Discov Today; 2005 May 15; 10(10):703-10. PubMed ID: 15896683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.